The vaccine and other medication
The manufacturer’s information for healthcare professionals contains no information on interactions with any other medication (since this has not been studied.)
The vaccine and other vaccines
The manufacturer’s information for healthcare professionals contains no information on interactions with other vaccines.
However, both PHE COVID-19 Vaccination Programme Information for Healthcare Professionals and PHE Immunisation Against Infectious Disease (the Green Book) suggest interference between inactivated vaccines with different antigenic content is likely to be limited. Therefore, based on experience with other vaccines, any potential problem is most likely to result in a slightly attenuated immune response to one of the vaccines. When administering more than one vaccine at the same time there is no evidence of any safety concerns but it becomes difficult to attribute any adverse effects to any particular product.
Timing the vaccine with other vaccines
Based on the above, the advice is to:
- not routinely offer appointments to give this vaccine at the same time as other vaccines;
- to ideally allow an interval of at least 7 days between administration of this vaccine and other vaccines.
Patients who received another vaccine 7 days before or after AstraZeneca COVID-19 vaccine
PHE COVID-19 Vaccination Programme Information for Healthcare Professionals and PHE Immunisation Against Infectious Disease (the Green Book) advise eligible individuals should still be considered for COVID-19 vaccination to avoid any further delay in protection and to avoid the risk of the patient not returning for a later appointment. In such circumstances, patients should be informed about the likely timing of potential adverse events relating to each vaccine.
The vaccine and COVID-19 treatments
PHE COVID-19 Vaccination Programme Information for Healthcare Professionals suggests that, as the COVID-19 vaccines are non-live vaccines, COVID-19 treatments such as dexamethasone, convalescent plasma or monoclonal antibody treatment are not anticipated to contraindicate vaccine administration. Although theoretically, high levels of antibodies in the convalescent plasma could interfere with the immune response to the vaccine, passively acquired antibodies from the plasma treatment are not thought to persist for long, so by the time a person who has received this is well enough to receive a COVID-19 vaccination, these antibodies are likely to have gone.
In addition, as COVID-19 vaccines do not contain a live virus, response to vaccination will not be affected by prior or recent anti-viral medication.
Mixing the vaccine with other products
Section 6.2 of the manufacturer’s information for healthcare professionals states that in the absence of compatibility studies the vaccine must not be mixed with other medicinal products.